Your browser doesn't support javascript.
loading
Characteristics of subjective cognitive decline associated with amyloid positivity.
Janssen, Olin; Jansen, Willemijn J; Vos, Stephanie J B; Boada, Merce; Parnetti, Lucilla; Gabryelewicz, Tomasz; Fladby, Tormod; Molinuevo, José Luis; Villeneuve, Sylvia; Hort, Jakub; Epelbaum, Stéphane; Lleó, Alberto; Engelborghs, Sebastiaan; van der Flier, Wiesje M; Landau, Susan; Popp, Julius; Wallin, Anders; Scheltens, Philip; Rikkert, Marcel Olde; Snyder, Peter J; Rowe, Chris; Chételat, Gaël; Ruíz, Agustin; Marquié, Marta; Chipi, Elena; Wolfsgruber, Steffen; Heneka, Michael; Boecker, Henning; Peters, Oliver; Jarholm, Jonas; Rami, Lorena; Tort-Merino, Adrià; Binette, Alexa Pichet; Poirier, Judes; Rosa-Neto, Pedro; Cerman, Jiri; Dubois, Bruno; Teichmann, Marc; Alcolea, Daniel; Fortea, Juan; Sánchez-Saudinós, M Belén; Ebenau, Jarith; Pocnet, Cornelia; Eckerström, Marie; Thompson, Louisa; Villemagne, Victor; Buckley, Rachel; Burnham, Samantha; Delarue, Marion; Freund-Levi, Yvonne.
Afiliação
  • Janssen O; Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Jansen WJ; Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Vos SJB; Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Boada M; Fundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
  • Parnetti L; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Gabryelewicz T; Section of Neurology, Center for Memory Disturbances - Lab. of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • Fladby T; Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
  • Molinuevo JL; Department of Neurology, Akershus University Hospital, Lorenskog, Norway.
  • Villeneuve S; Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Hort J; Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
  • Epelbaum S; Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
  • Lleó A; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
  • Engelborghs S; AP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
  • van der Flier WM; Inserm Sorbonne Université, Inria, Aramis project-team, Paris Brain Institute - Institut du Cerveau (ICM), Paris, France.
  • Landau S; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
  • Popp J; Vrije Universiteit Brussel, (VUB) Brussels, and University of Antwerp, Antwerp, Belgium.
  • Wallin A; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Scheltens P; Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.
  • Rikkert MO; Department of Geriatric Psychiatry, Psychiatric University Hospital, Zürich, Switzerland.
  • Snyder PJ; Old Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.
  • Rowe C; CSIRO Health & Biosecurity, Parkville, Victoria, Australia.
  • Chételat G; Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
  • Ruíz A; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Marquié M; Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Chipi E; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Wolfsgruber S; Kingston, The University of Rhode Island, Rhode Island, USA.
  • Heneka M; Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia.
  • Boecker H; Institut National de la Sant. et de la Recherche M.dicale (Inserm), Caen, France.
  • Peters O; Fundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
  • Jarholm J; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Rami L; Fundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
  • Tort-Merino A; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Binette AP; Section of Neurology, Center for Memory Disturbances - Lab. of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • Poirier J; German Center For Neurodegenerative Diseases/Clinical Research, Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Zentrum für klinische Forschung/AG, Cologne, Germany.
  • Rosa-Neto P; Department of Neurodegenerative Diseases and Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Cerman J; Department of Neurodegenerative Diseases and Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Dubois B; Functional Neuroimaging Group, Department of Radiology, University Hospital Bonn, Bonn, Germany.
  • Teichmann M; Klinik für Psychiatrie und Psychotherapie, Charité Universitätsmedizin Berlin - CBF, Berlin, Deutschland.
  • Alcolea D; Department of Neurology, Akershus University Hospital, Lorenskog, Norway.
  • Fortea J; Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Sánchez-Saudinós MB; Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Ebenau J; Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
  • Pocnet C; Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
  • Eckerström M; Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
  • Thompson L; Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
  • Villemagne V; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
  • Buckley R; AP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
  • Burnham S; AP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
  • Delarue M; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
  • Freund-Levi Y; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
Alzheimers Dement ; 18(10): 1832-1845, 2022 10.
Article em En | MEDLINE | ID: mdl-34877782
ABSTRACT

INTRODUCTION:

The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited.

METHODS:

In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity.

RESULTS:

Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages.

DISCUSSION:

Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Amiloidose Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Amiloidose Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda